中国骨科,凛冬已逝

医曜
Jan 16

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。历经四年集采洗礼,曾深陷寒冬的中国骨科企业,终于迎来价值回归的曙光。回望2025年,中国骨科板块走出强劲行情。在春立医疗、大博医疗的强势引领下,全年骨科头部企业股价平均涨幅达24.82%;除因股权争夺陷入ST的凯利泰外,其余头部企业均实现股价上涨,行业复苏态势清晰可见。图:中国主要骨科公司2025年股价,来源:锦缎研究院时间回溯至...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10